D
Dupilumab [Dupixent]
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
No
Active ingredient: Dupilumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
06/02/2026 Biologics as add-on therapy for severe asthma
The Ministry of Health’s Drug Advisory Committee has recommended:
Benralizumab 30 mg/1 mL autoinjector pen for treating severe eosinophilic asthma; and
Omalizumab biosimilar (Omlyclo) 75 mg/0.5 mL and 150 mg/1 mL pre-filled syringes for treating severe allergic asthma.
Funding status
[R] Benralizumab 30 mg/ml autoinjector pen is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.
[R] Benralizumab should be used in line with the additional clinical criteria for initiation and renewal listed in the Annex.
[R] Omalizumab biosimilar (Omlyclo) 75 mg/0.5 mL and 150 mg/1 mL pre-filled syringes are recommended for inclusion on the Standard Drug List (SDL) from 1 April 2026.
[NR] SDL subsidy and MAF assistance do not apply to any formulations or strengths of dupilumab, mepolizumab, omalizumab reference biologic (Xolair) or tezepelumab for treating severe asthma.
02/01/2024 Abrocitinib, baricitinib, upadacitinib and dupilumab for treating atopic dermatitis
The Ministry of Health’s Drug Advisory Committee has recommended:
Abrocitinib 50 mg, 100 mg and 200 mg film-coated tablets for treating moderate-to-severe atopic dermatitis in patients who have had an inadequate response, intolerance or contraindication to at least one systemic therapy such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil.
Funding status
[R] Abrocitinib 50 mg, 100 mg and 200 mg film-coated tablets are recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indication from 1 March 2024.
[R] Abrocitinib should be used in line with additional clinical criteria for initial and continuing prescriptions for patients with moderate-to-severe atopic dermatitis.
[NR] MAF assistance does not apply to any formulations or strengths of baricitinib, upadacitinib or dupilumab for treating atopic dermatitis.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Dupixent Injection, Solution (Pre-Filled Syringe) 300 mg/2 mL |
|
Dupixent Injection, Solution (Pre-Filled Syringe) 200 mg per 1.14 mL |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Subcutaneous
DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 MG/1.14ML [SIN16121P]*
DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 300 MG/2ML [SIN15675P]*
DUPIXENT SOLUTION FOR INJECTION IN A PRE‐FILLED PEN 200 MG/1.14ML [SIN17291P]*
DUPIXENT SOLUTION FOR INJECTION IN A PRE‐FILLED PEN 300 MG/2ML [SIN17292P]*
* Clinical information is available for this product.